# Grifols Company radar · 385 documents · 2021-01-01–2026-10-20 · updated 2026-10-31 Canonical: https://slate.greyb.com/radar/grifols/innovations ## In one minute ### The immunoglobulin process has lost most of its equipment Ethanol fractionation and cold precipitation were how a litre of plasma became IgG. The filings have been removing vessels from that sequence. A polyanionic pre-treatment binds lipids and fibrinogen ahead of chromatography so the resin does not foul, and the applicant states yield rises from 65% to 90% [1]. An earlier step removed a different unit operation: caprylic acid inactivates enveloped viruses, polyethylene glycol suppresses the aggregates caprylate would otherwise form, and one ultrafiltration pass strips both reagents, so no follow-up chromatography is needed [2] [3]. The 90% figure is the applicant's own and has not been shown independently. The direction, fewer steps and more protein out of the same litre, is consistent across the family. IgM got the same scrutiny with different chemistry: PEG precipitation, isolectin removal by affinity chromatography, arginine holding the pentamer apart, then lyophilisation with amino acids and polysorbate to keep more than 90% of it in pentameric form [4] [5]. 1. [WO2026190134A1](/?paper=WO2026190134A1&utm_source=radar&utm_medium=dashboard) 2. [AU2016231646B2](/?paper=AU2016231646B2&utm_source=radar&utm_medium=dashboard) 3. [MX384535B](/?paper=MX384535B&utm_source=radar&utm_medium=dashboard) 4. [CN115768789A](/?paper=CN115768789A&utm_source=radar&utm_medium=dashboard) 5. [US2024417445A1](/?paper=US2024417445A1&utm_source=radar&utm_medium=dashboard) ### Immunoglobulin pays for the group and the fastest growth is under the skin In the first half of 2026 group revenue reached €3,574 million, up 2.6% at constant currency, and net profit rose 28.7% to €227 million. Within that, intravenous immunoglobulin grew 12.5% and subcutaneous immunoglobulin 17.7%, the immunoglobulin segment as a whole grew 12.8% at constant rates, and Xembify grew 34% in the second quarter. Guidance was reiterated after a half described as in line with objectives. ### The portfolio has narrowed back onto plasma Plasma Protein Therapeutics accounts for 217 of the 385 publications, Diagnostics 98 and Manufacturing and Fill-Finish 69. That balance understates the swing inside the period. ### Concentration is what moves a protein out of the infusion chair Delivery changes are formulation problems before they are clinical ones. Alpha-1 antitrypsin reaches 100 to 200 mg/mL by single-pass tangential filtration against water, a route chosen because concentrating that far by conventional means aggregates the protein. That concentration is what makes a weekly subcutaneous dose possible at roughly 120% of the intravenous dose, holding the same trough level. ### The albumin decline now has a tax change behind it Albumin fell about 20% in the second quarter. In China the average selling price is down 2% year to date, rivals are discounting 5 to 10% below the floor Hualan set, and lot releases fell 25% between October 2025 and April 2026. ### The 2026 plasma output is the same inventions in more countries Where the work lands matters more than how much of it there is. Brazil carries 16 plasma patents, China 14, Europe 14 and the United States 14, with the rest spread across Japan, Australia, Canada, South Africa, India and Mexico. Diagnostics runs the other way, with 17 of its patents published in China against 16 in the United States. ### Two programmes leave the syringe and the litre behind The most recent clinical move is immunoglobulin used as a topical drug. GRF312 is a 5% immunoglobulin eye drop for dry eye disease. The FDA cleared the investigational application in May 2025, and the phase 2 was designed for 100 patients with safety and tolerability as the primary measure. The premise is that the antibody mixture's broad anti-inflammatory action works on the surface of the eye, which the company describes as a potential first ocular-surface indication for an immunoglobulin. ### Egypt now carries the margin case as much as the sourcing case The joint venture added €180 million for 2026 to 2029, taking total investment to €460 million, with the first phase of the complex due for inauguration in October 2026, a million litres collected this year and three million by 2029. The programme is certified by the European Medicines Agency, and 1.6 million vials have already been produced from Egyptian plasma. Its attributed contribution to group EBITDA exceeds €100 million in 2026. Fractionation does not start until late 2027 or early 2028, with full operation in 2030. ## Overview Grifols is a plasma fractionator that owns two smaller businesses, and its portfolio turns on one question: which parts of a litre of plasma survive being made some other way. The answer in this period is immunoglobulin and the clotting complex. The patent effort defends those two, while the one easily copied protein, albumin, is repriced by a competitor that is not a fractionator at all. ## What's new October added three documents across two areas, and each is an existing Grifols invention reaching a new jurisdiction. None introduces a new therapy or a new trial. ## Research ### One protein-engineering trick makes the whole reagent catalogue Diagnostics rests on a repeatable construction. Take the outside portion of a receptor or a viral protein, the part a drug binds, and fuse it to a domain that forces several copies together: an antibody Fc region, a p53 tetramer, a GCN4 or clathrin trimer, often with a polyhistidine tag for purification. The target becomes soluble and multivalent, so it captures the drug it is meant to measure with high avidity, and it can be grown in CHO or HEK293 cells. ### The instrument side moved from reading a card to routing a tube The older analyzers performed immunohematology chemistry on gel cards. The 2026 hardware does logistics: a puck on a rail that carries a tube between instruments, a rack laid out so a robot never lifts one tube over a neighbour, a gripper that holds a tube by the wall so the label and closure survive, and software that sends each sample to whichever analyzer runs its test, with urgent samples jumping the queue. Much of this is co-assigned with Gen-Probe, which ties the blood-bank line to donor-screening hardware as well as to assay chemistry. ### The filling line moved the sterile boundary into the container The engineering argument is that a depyrogenation tunnel heats containers enough to damage them, so sterilisation moves to autoclaves. An autoclave works in batches and a filler needs a steady stream, so the line is completed by an accumulation plate between the two and a switching device that diverts containers while one autoclave is in cycle. ### The boundary of what exists What has been built is a fractionator whose chemistry sheds vessels at each revision, four ways to reach a patient, a reagent toolkit that re-aims at every new drug that interferes with a test, a tube-handling platform shared with a donor-screening partner, and a sterile line sold to other manufacturers. Everything in the plasma business still begins with a donation. ## Strategy ### The partner list has been replaced by subsidiaries and clinical investigators The names beside Grifols have turned over completely. The 2021 publications are co-assigned with companies from its own history: Talecris, Probitas, Medion Diagnostics and Chiron, plus single filings with Novartis, Ortho Clinical Diagnostics and Janssen. None of those names appears on a 2026 publication. ### One instrument maker carries the hardware line Gen-Probe is the only industrial collaboration that has run continuously, and it is entirely about moving tubes. The 2026 co-assigned patents cover a puck carrying a sample between instruments, a rack laid out so no tube passes over another, routing that lets urgent samples jump the queue, instruments exchanging control lots over a network, and a malaria nucleic-acid test. ### The evidence base is co-authored by a small set of Spanish centres Of 105 papers, 82 carry academic co-authors, and the same institutions recur. The Alzheimer's programme publishes with Hospital Clínic de Barcelona, IDIBAPS, the Lleida biomedical institute and the Spanish neurodegeneration network. The cirrhosis health-economics work runs through the European liver foundation and the same Barcelona group. The soluble CD38 evaluation is a six-country laboratory study coordinated with blood services in Switzerland, Scotland, Italy and Spain. ### Clinical work now widens existing labels The 2021 trials were pandemic bets: convalescent-derived hyperimmune globulin in asymptomatic infection, and alpha-1 in hospitalised COVID-19. Everything from 2024 onward extends products already sold. ### The engineering line has stopped growing Fill-finish output fell from 24 publications in 2021 to 6 in 2023, rose to 13 in 2024, and has held at 7 in each of the last two periods. Its 69 publications make it the third pillar of the portfolio on paper, and the smallest by recent output. ### What the shift does to the picture Three businesses were being filed in parallel in 2021. By 2026 one of them absorbs two thirds of the output, and it is the one whose patents are mostly older inventions reaching new markets. ## Areas - Plasma Protein Therapeutics · 217 documents - Diagnostics · 98 documents - Manufacturing and Fill-Finish · 69 documents